A year after revealing his “Liberation Day” trade policy initiatives, U.S. President Donald Trump is set to announce tariffs ...

Travere Therapeutics is awaiting an FDA decision on a label expansion for FILSPARI in focal segmental glomerulosclerosis, a ...

View Praxis Precision Medicines, Inc. PRAX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

Continued FDA approval of iptacopan was contingent on 2-year trial data ...

According to TipRanks.com, Skor is a 4-star analyst with an average return of 15.8% and a 61.2% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Dan Yoo took a breath before describing what he saw when he stopped into work on a Sunday morning at the Larry C. Hardy ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported fourth-quarter profit of $2.7 million. The San Diego-based company said it had net income of 3 cents per share.